271 related articles for article (PubMed ID: 15485466)
41. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
Lim WH; Russ GR; Coates PT
Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
[TBL] [Abstract][Full Text] [Related]
42. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical analysis and Epstein-Barr virus in the tonsils of transplant recipients and healthy controls.
Mowry SE; Strocker AM; Chan J; Takehana C; Kalantar N; Bhuta S; Shapiro NL
Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):936-9. PubMed ID: 18794437
[TBL] [Abstract][Full Text] [Related]
44. Evolution of PTLD following renal transplantation in a child.
Markert E; Siebolts U; Habbig S; Odenthal M; Dienes HP; Stippel DL; Hoppe B; Wickenhauser C
Pediatr Transplant; 2009 May; 13(3):379-83. PubMed ID: 19017284
[TBL] [Abstract][Full Text] [Related]
45. Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders.
Khedmat H; Alavian S; Taheri S
Ann Transplant; 2010; 15(2):40-4. PubMed ID: 20657518
[TBL] [Abstract][Full Text] [Related]
46. Brain tumor as an unusual presentation of posttransplant lymphoproliferative disorder.
Azarpira N; Torabineghad S; Rakei M
Exp Clin Transplant; 2009 Mar; 7(1):58-61. PubMed ID: 19364315
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients.
Toyoda M; Moudgil A; Warady BA; Puliyanda DP; Jordan SC
Pediatr Transplant; 2008 Nov; 12(7):778-84. PubMed ID: 18331541
[TBL] [Abstract][Full Text] [Related]
48. Post-transplant lymphoproliferative disorder with supraglottic involvement.
Rombaux P; Marque A; Hamoir M; Smets F; Sokal E
B-ENT; 2005; 1(1):53-6. PubMed ID: 15999677
[TBL] [Abstract][Full Text] [Related]
49. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression.
Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W
Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076
[TBL] [Abstract][Full Text] [Related]
50. [Quantitative analysis of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes in EBV-related diseases].
Kuzushima K
Rinsho Ketsueki; 2000 Jun; 41(6):487-90. PubMed ID: 10921347
[No Abstract] [Full Text] [Related]
51. Early posttransplant lymphoproliferative disease in pediatric liver transplant recipients.
Roque J; Rios G; Humeres R; Volpi C; Herrera JM; Schultz M; Rios H; Rius M; Salgado C; Hepp J
Transplant Proc; 2006 Apr; 38(3):930-1. PubMed ID: 16647513
[TBL] [Abstract][Full Text] [Related]
52. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient.
Nanmoku K; Shinzato T; Kubo T; Shimizu T; Yagisawa T
Transpl Infect Dis; 2019 Aug; 21(4):e13116. PubMed ID: 31102475
[TBL] [Abstract][Full Text] [Related]
53. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.
Muzaffar M; Taj A; Ratnam S
Am J Ther; 2010; 17(6):e230-3. PubMed ID: 19918163
[TBL] [Abstract][Full Text] [Related]
54. Posttransplant lymphoproliferative disorders in transplant recipients.
Timurağaoğlu A; Uğur-Bilgin A; Colak D; Tuncer M; Gölbaşi I; Hazar V; Kiliçarsłan B; Undar L; Demirbaş A
Transplant Proc; 2006 Mar; 38(2):641-5. PubMed ID: 16549195
[TBL] [Abstract][Full Text] [Related]
55. Incidence of reactive antibodies against epstein-barr in a group of renal transplant patients.
Geramizadeh B; Aghdai M; Azarpira N; Behabahani AB; Heidari T; Banihashemi M; Raisjalali AR; Roozbeh J; Behzadi A
Transplant Proc; 2005 Sep; 37(7):3051-2. PubMed ID: 16213301
[TBL] [Abstract][Full Text] [Related]
56. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
Dolcetti R
Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
[TBL] [Abstract][Full Text] [Related]
57. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
[TBL] [Abstract][Full Text] [Related]
58. Asymptomatic post-transplant lymphoproliferative disorder diagnosed at one year protocol renal allograft biopsy.
Kitajima K; Sasaki H; Koike J; Nakazawa R; Sato Y; Yazawa M; Tsuruoka K; Kawarazaki H; Imai N; Shirai S; Shibagaki Y; Chikaraishi T
Nephrology (Carlton); 2014 Jun; 19 Suppl 3():42-4. PubMed ID: 24842822
[TBL] [Abstract][Full Text] [Related]
59. Immune-cell treatment of Epstein--Barr-virus-associated lymphoproliferative disorders.
Swinnen LJ
Best Pract Res Clin Haematol; 2006; 19(4):839-47. PubMed ID: 16997187
[TBL] [Abstract][Full Text] [Related]
60. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
